-
公开(公告)号：US07863300B2
公开(公告)日：2011-01-04
申请号：US12010473
申请日：2008-01-25
IPC分类号： A61K31/4436 , C07D417/12
CPC分类号： C07D213/30 , C07D213/34 , C07D417/12
摘要： A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.
摘要翻译： 如所述制备噻唑烷二酮类，优选吡格列酮的新方法。 还描述了涉及其合成的新型中间体及其在医药中的制备和应用的方法。
-
42.发明申请公开(公告)号：US20100273791A1
公开(公告)日：2010-10-28
申请号：US12769861
申请日：2010-04-29
IPC分类号： A61K31/416 , C07D231/54 , C07D491/044 , C07D495/04 , A61K31/454 , A61K31/4162 , A61K31/5377 , A61K31/496 , C07C69/738 , C07D313/08 , C07D337/08
CPC分类号： C07D495/14 , C07D495/04
摘要： The present invention relates to novel compounds of general formula (I), their regioisomers, tautomeric forms, novel intermediates involved in their synthesis. The present invention also relates to a process of preparing compounds of general formula (I), their regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
摘要翻译： 本发明涉及通式（I）的新型化合物，其区域异构体，互变异构体，涉及其合成的新型中间体。 本发明还涉及制备通式（I）的化合物，其区域异构体，其互变异构形式，其药学上可接受的盐，含有它们的药物组合物以及参与其合成的新中间体的方法。
-
公开(公告)号：US20080139574A1
公开(公告)日：2008-06-12
申请号：US11998448
申请日：2007-11-29
IPC分类号： A61K31/496 , C07D401/10 , A61P31/04
CPC分类号： C07D401/04 , C07D215/56 , C07D405/12 , C07D409/12
摘要： The present invention relates to novel compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process for preparing compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts and pharmaceutical compositions containing them.
摘要翻译： 本发明涉及通式（I）的新化合物，其互变异构形式，其药学上可接受的盐和含有它们的药物组合物。 本发明还涉及制备通式（I）的化合物，其互变异构形式，其药学上可接受的盐和含有它们的药物组合物的方法。
-
公开(公告)号：US20220339124A1
公开(公告)日：2022-10-27
申请号：US17765030
申请日：2020-09-30
发明人： Kannan Essakimuthu MUTHAIYYAN , Ritu Nitin LADDHA , Harish PAWAR , Shailesh Arvindbhai PATEL , Jay Shantilal KOTHARI
IPC分类号： A61K31/135 , A61K9/00 , A61K9/08
摘要： The present invention relates to intranasal pharmaceutical compositions comprising cyclobenzaprine or salts thereof for the treatment or management of muscle spasms in musculoskeletal diseases and/or painful physical symptoms in neurological diseases. In particular, the invention relates to intranasal pharmaceutical compositions comprising cyclobenzaprine or salts thereof and one or more pharmaceutically acceptable excipients.
-
公开(公告)号：US20220289846A1
公开(公告)日：2022-09-15
申请号：US17625551
申请日：2020-07-09
发明人： Sanjeev Kumar MENDIRATTA , Kaushik BANERJEE , Dipti MEHTA , Ramkrashan KASERA , Arun SINGH , Aashini PARIKH , Pankaj KALITA , Ritu UPADHYAY , Vibhuti SHARMA , Hardik PANDYA
摘要： The present invention relates to an antibody or antigen-binding portion thereof that can bind to human programmed death 1 (PD-1). The antibody according to the present invention is further used in the preparation of a drug for treating disease in which expression of PD-1 is detrimental.
-
公开(公告)号：US20220071954A1
公开(公告)日：2022-03-10
申请号：US17414733
申请日：2019-12-17
发明人： Mukul R. JAIN , Suresh GIRI
摘要： The present invention relates to pharmaceutical compositions containing the formula (I) for the prevention, delay of progression, or treatment of a disease or condition from hepatocellular carcinoma. The present invention further provides the composition of formula (I) useful in the prevention and treatment of hepatocellular carcinoma.
-
公开(公告)号：US11254675B2
公开(公告)日：2022-02-22
申请号：US16991323
申请日：2020-08-12
IPC分类号： C07D471/06 , A61K31/64 , C07D213/76
摘要： The invention relates to process for the preparation of grapiprant and its intermediates thereof. The invention also relates to grapiprant having a purity 98% or more and compounds of Formula (A), (B), (C) and (D) in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC. The invention also relates to an amorphous form of grapiprant and process for preparation thereof.
-
公开(公告)号：US20210330801A1
公开(公告)日：2021-10-28
申请号：US16490208
申请日：2018-03-01
摘要： The invention provides stable pharmaceutical formulation comprising a protein drug conjugate along with one or more suitable excipient(s) such that the formulation is devoid of any buffer components and methods of making the same. The protein drug conjugate according to the present invention is antibody drug conjugate, preferably trastuzumab maytansinoid conjugate. Suitable excipient(s) according to the present invention is selected from suitable bulking agents, suitable tonicity modifiers, suitable stabilizers and the like.
-
49.发明申请公开(公告)号：US20210292333A1
公开(公告)日：2021-09-23
申请号：US17252494
申请日：2019-06-14
发明人： Ranjit DESAI , Vrajesh PANDYA , Mehul PUJARA , Anil ARGADE , Jignesh JOSHI , Anshul SATYANAND
IPC分类号： C07D487/04 , C07D471/04 , A61K45/06 , A61P31/04
摘要： Present invention relates to novel compound of general formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection. The compounds of general formula (I) exhibit DprE1 enzyme inhibitory activity.
-
公开(公告)号：US20210267953A1
公开(公告)日：2021-09-02
申请号：US17262278
申请日：2019-07-24
发明人： Ranjit DESAI , Vrajesh PANDYA , Mehul PUJARA , Anil ARGADE , Jignesh JOSHI , Anshul SATYANAND
IPC分类号： A61K31/438 , A61P31/04 , C07D495/10 , C07D491/107 , C07D413/14 , A61K31/454 , A61K31/496 , A61K31/7036 , A61K31/5383 , A61K31/606 , A61K31/4409 , A61K31/133 , A61K31/4965
摘要： Present invention relates to novel compound of formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection.
-
-
-
-
-
-
-
-
-
搜索结果
286 条记录 (耗时 0.022 秒)
